Judgements

Content in the run’s language (EN)

240 judgements

Pair	Criterion	Decision	Judge	Confidence	Rationale	Missing evidence	Evidence
ALK — EGFR	Modality–direction–exposure fit	Abstained	gpt-5.6-luna	94%	Both candidates have strong evidence that inhibition by an oral small molecule is an established modality: ALK has multiple approved small-molecule inhibitors and systemic/CNS clinical activity, while EGFR likewise has multiple approved TKI generations. However, the criterion requires fit to direction, modulation depth and duration, tissue exposure, and biodistribution in the specified lung and mucus-producing glandular-cell context. The dossiers do not provide comparative PK/PD, target-turnover, delivery, biodistribution, or direct target-engagement data for that cell type. ALK evidence localizes mainly to malignant lung epithelial or alveolar contexts, while EGFR evidence is broader epithelial evidence without specific confirmation in mucus-producing glandular cells. The available modality precedent is therefore insufficient to adjudicate the required modality–direction–exposure fit without treating missing exposure evidence as evidence against either candidate.	Comparative PK/PD modelling for the proposed small molecules, including depth and duration of ALK or EGFR inhibition in the specified mucus-producing glandular cells Target-turnover and required exposure-duration data for ALK versus EGFR in the relevant NSCLC cell context Direct lung delivery, tissue-penetration, intracellular target-engagement, and biodistribution data in mucus-producing glandular-cell tumors or matched PDX models Evidence that either target is present and actionable specifically in the specified mucus-producing glandular tumor-cell population rather than in other epithelial or alveolar contexts	Several approved ALK TKIs ALK is clinically tractable with an established oral small-molecule kinase-inhibitor modality in metastatic NSCLC. First-line ALK inhibition produces strong systemic and intracranial clinical efficacy, supporting high tractability of ALK in NSCLC. Multiple approved TKI generations In NSCLC, oncogenic ALK is found in malignant lung epithelial tumor cells, predominantly as an EML4–ALK fusion in a molecular subset of tumors. Alveolar epithelial cells can serve as a relevant lung cellular context for EML4–ALK-driven tumorigenesis in vivo. In welchen krankheitsrelevanten Zelltypen wird EGFR exprimiert? Wie hoch ist die Abundanz von EGFR, angegeben in Transkripten pro Million oder Proteinkopien pro Zelle, bei einem bestimmten Krankheitszustand?
ALK — MET	Perturbational evidence	B wins	gpt-5.6-luna	90%	MET has stronger reproducible PDX perturbational evidence: selective MET inhibition produced antitumor responses across six MET-amplified patient-derived xenograft models, and an independent set of six EGFR-mutant, MET-amplified patient-derived models responded to MET inhibition alone in vitro and in vivo (C2-EV_PERTURBATION_0002, C2-EV_PERTURBATION_0003). Genetic MET knockdown supports on-target dependence, although it uses shRNA and is therefore weaker alone (C2-EV_PERTURBATION_0001). ALK has evidence of selective siRNA effects and a limited patient-derived model mention, but the dossier does not provide comparably detailed, reproducible PDX tumor-response evidence; its CRISPR evidence primarily concerns resistance mechanisms rather than reversal of disease-relevant phenotypes (C1-EV_PERTURBATION_0001, C1-EV_PERTURBATION_0002).	A directly comparable ALK PDX study with quantified tumor-response results and orthogonal ALK perturbations, rather than the limited knockdown evidence described in C1-EV_PERTURBATION_0001.	Pharmacologic MET inhibition suppresses MET-dependent lung cancer models in vitro and in vivo, with sensitivity linked to MET signaling complexes. A subset of EGFR-mutant, MET-amplified NSCLC models becomes dependent on MET and responds to MET inhibition alone. MET knockdown selectively impairs growth and survival of MET-amplified NSCLC cell lines. MET perturbational dependency in NSCLC is restricted to a molecularly defined subset rather than being general across lung cancer models. CRISPR MET knockout in A549 NSCLC cells did not materially impair intrinsic proliferation, despite reducing dissemination-related phenotypes. CRISPR loss of KEAP1 can produce resistance to ALK inhibition in ALK-mutant lung cancer models. Genome-wide CRISPR knockout identified MIG6/ERRFI1 loss as a mechanism of resistance to ALK TKIs through EGFR bypass signaling.
MET — KRAS	Patient stratification	A wins	gpt-5.6-luna	94%	MET has the clearest operationalized patient-selection hypothesis: MET exon 14 skipping was prospectively assayed using tissue RNA or plasma cfDNA/NGS, linked to response in a defined NSCLC population, and incorporated into FDA-approved testing and indications (C1-EV_BIOMARKER_0001, C1-EV_CLINICAL_0003, C1-EV_TRACTABILITY_0002). KRAS has strong genomic evidence for recurrent, prospectively identifiable molecular subsets and established mutant-selective small-molecule tractability (C2-EV_GENETICS_0003, C2-EV_TRACTABILITY_0001), but the supplied dossier does not provide comparably direct evidence of a prospectively specified, biomarker-selected NSCLC treatment study. MET therefore supports the clearer prospectively testable selection hypothesis.	For KRAS: a prospective NSCLC treatment-selection study using a prespecified genomic assay and reporting outcomes for a defined KRAS molecular subgroup, particularly KRAS G12C, rather than evidence limited to prospective prevalence profiling or general clinical tractability.	MET exon 14 skipping is a clinically validated predictive biomarker for selective MET inhibition in NSCLC. Capmatinib is FDA-indicated for metastatic NSCLC with a mutation leading to MET exon 14 skipping, selected using an FDA-approved test. MET is clinically tractable in NSCLC through genotype-selected, oral small-molecule kinase inhibition of MET exon 14–skipping tumors. MET exon 14 skipping is clinically validated as a predictive biomarker in metastatic NSCLC through durable responses to selective MET inhibitors. Independent prospective clinical sequencing confirms KRAS as one of the dominant oncogenic drivers in metastatic human lung adenocarcinoma. Clinically validated tractability MET biomarker classification is substantially affected by intratumoral heterogeneity and discordance between assays. MET amplification has weaker and threshold-dependent clinical validation than MET exon 14 skipping in NSCLC.
ALK — MET	Cell and tissue relevance	Abstained	gpt-5.6-luna	97%	Both dossiers provide human NSCLC tissue evidence, but neither directly evaluates the specified mucus-producing glandular cells. ALK is localized generally to malignant pulmonary epithelial/adenocarcinoma cells (C1-EV_TISSUE_0001, C1-EV_TISSUE_0002, C1-EV_TISSUE_0006), while MET is detected generally in neoplastic tumor cells by immunohistochemistry (C2-EV_TISSUE_0001, C2-EV_TISSUE_0002). These broader tissue findings do not establish expression, localization, or dysregulation in the critical cell type, and the MET evidence specifically shows substantial heterogeneity and poor correspondence between protein expression and actionable genomic alterations (C2-EV_TISSUE_0004, C2-EV_TISSUE_0006). Because the required cell-specific evidence is missing for both candidates, the appropriate verdict is ABSTAIN rather than ranking one lower for being understudied.	Single-cell or spatially resolved evidence directly localizing ALK or MET expression and dysregulation to mucus-producing glandular cells in human NSCLC, with control for cell-composition shifts and disease stage. Direct comparative pathology or proteomic evidence in the specified mucus-producing glandular-cell compartment establishing target dysregulation rather than altered abundance of that cell type.	–
MET — ALK	Translational model validity	B wins	gpt-5.6-luna	78%	ALK has a slightly stronger translational validity dossier because efficacy is supported across mechanistically relevant genetically engineered lung-tumor models, patient-derived NSCLC models, direct genetic perturbation, and multiple randomized first-line clinical studies in untreated advanced ALK-positive NSCLC. MET also has strong patient-derived xenograft evidence and clinically active biomarker-selected therapy, but its model evidence is concentrated in MET-amplified subsets and is more explicitly alteration- and context-dependent. The advantage for ALK is narrow because ALK dependency is heterogeneous across models and variant-specific, while neither dossier supplies direct human organoid, ex vivo tissue, or humanised-model efficacy evidence.	Direct head-to-head comparison of MET and ALK in matched human organoid, primary patient-cell, ex vivo tissue, humanised, or patient-derived models from newly diagnosed NSCLC; the dossiers provide no human organoid or ex vivo tissue efficacy studies.	The EML4 portion of EML4-ALK promotes cytoplasmic phase-separated condensates that organize downstream signaling, including STAT3 activation, and support lung tumorigenesis. Alveolar epithelial cells can serve as a relevant lung cellular context for EML4–ALK-driven tumorigenesis in vivo. Direct ALK knockdown selectively impairs viability and clonogenic growth of EML4-ALK-positive NSCLC cells. ALK signaling is essential for proliferation and survival in at least a subset of EML4-ALK-positive NSCLC models. ALK is clinically validated as a predictive therapeutic biomarker in advanced NSCLC by randomized phase 3 evidence showing superior efficacy of ALK inhibition over platinum-pemetrexed chemotherapy. Lorlatinib provides durable long-term clinical benefit in treatment-naive advanced ALK-positive NSCLC, with sustained systemic and intracranial disease control. Pharmacologic MET inhibition suppresses MET-dependent lung cancer models in vitro and in vivo, with sensitivity linked to MET signaling complexes. A subset of EGFR-mutant, MET-amplified NSCLC models becomes dependent on MET and responds to MET inhibition alone. ALK rearrangement does not uniformly establish ALK pathway dependence across NSCLC models. ALK fusion variants produce materially different pathway dependency and inhibitor sensitivity. CRISPR-based in vivo perturbation shows that EML4-ALK variants are functionally heterogeneous rather than a uniform dependency context. MET perturbational dependency in NSCLC is restricted to a molecularly defined subset rather than being general across lung cancer models. CRISPR MET knockout in A549 NSCLC cells did not materially impair intrinsic proliferation, despite reducing dissemination-related phenotypes. MET amplification has weaker and threshold-dependent clinical validation than MET exon 14 skipping in NSCLC.
KRAS — EGFR	Competitive differentiation	Abstained	gpt-5.6-luna	96%	The dossiers support scientific target validity and small-molecule tractability for both KRAS and EGFR, including mutant-selective or mutation-directed mechanisms (C1-EV_TRACTABILITY_0001, C1-CAT-ONCO-BIO-091b, C2-EV_TRACTABILITY_0001, C2-CAT-ONCO-BIO-091b). However, Q11 asks for competitive differentiation over chemotherapy in newly diagnosed NSCLC. Neither dossier provides a direct newly diagnosed comparison, a chemotherapy-specific unmet-need analysis, or sufficient competitor-pipeline evidence to establish clinically meaningful differentiation. The available evidence therefore cannot distinguish the candidates under this criterion without conflating scientific merit with market attractiveness.	Direct clinical or translational evidence in newly diagnosed NSCLC comparing KRAS- or EGFR-directed therapy, alone or with chemotherapy, against chemotherapy on clinically meaningful outcomes. A current-treatment-landscape and unmet-need analysis specific to newly diagnosed NSCLC receiving chemotherapy. Evidence defining the relevant biomarker-selected population, treatment setting, comparator regimen, and magnitude of benefit for either target over chemotherapy. A candidate-specific competitor-pipeline comparison for the proposed small-molecule intervention.	–
ALK — MET	Human natural experiments	Abstained	gpt-5.6-luna	98%	Neither dossier provides the rubric-specified human natural-experiment evidence. The dossiers contain somatic tumor alterations, preclinical perturbations, animal knockout data, and clinical treatment studies, but these do not establish human biobank LoF, protective-allele, Mendelian-disease, or long-term drug-exposure evidence for inhibition. Therefore there is no admissible basis to compare ALK and MET under Q4.	Human biobank loss-of-function phenotypes, protective-allele studies, Mendelian disease evidence, or long-term pharmacological exposure cohorts for ALK and MET in NSCLC, including evidence that the human genetic or exposure direction matches therapeutic inhibition and supports both efficacy and tolerability.	–
EGFR — MET	Combination potential	Abstained	gpt-5.6-luna	98%	Neither dossier provides direct evidence for combination with chemotherapy. The dossiers contain resistance and pathway-combination evidence for EGFR–MET co-inhibition (C1-CAT-ONCO-BIO-004, C1-CAT-ONCO-BIO-013, C2-EV_MECHANISM_0004, C2-EV_MECHANISM_0005), but this does not establish rationale for chemotherapy combinations. EGFR has evidence of on-target dermatologic and gastrointestinal toxicity (C1-EV_SAFETY_0001), while MET has evidence of clinically relevant edema, pulmonary, hepatic, and pancreatic toxicities (C2-EV_SAFETY_0004, C2-EV_SAFETY_0006, C2-EV_SAFETY_0007); however, no dossier item assesses overlap with chemotherapy toxicity or whether the combinations can be dosed safely together. Because the criterion specifically requires combination evidence and the guardrail makes safe co-dosing necessary, there is insufficient evidence to rank either candidate.	For both EGFR and MET: direct chemotherapy-combination preclinical studies in NSCLC, including pathway-complementarity or additive/synergistic efficacy, resistance-mechanism testing, and a formal overlapping-toxicity/doseability assessment in relevant in vivo models.	–
EGFR — ALK	Modality–direction–exposure fit	B wins	gpt-5.6-luna	72%	Both targets have strong small-molecule modality precedent and an inhibition direction compatible with the proposed intervention. ALK has the stronger modality–exposure precedent: multiple approved oral ALK inhibitors, regulatory confirmation of oral dosing, and clinical evidence of systemic and intracranial activity, supporting effective tissue delivery and durable pharmacologic modulation (C2-EV_TRACTABILITY_0001, C2-EV_TRACTABILITY_0002, C2-EV_TRACTABILITY_0003, C2-EV_TRACTABILITY_0004). EGFR also has established small-molecule tractability through multiple approved TKI generations (C1-EV_TRACTABILITY_0001). However, neither dossier supplies direct PK/PD, target-turnover, or biodistribution data in the specified mucus-producing glandular cells. ALK's advantage is therefore narrow rather than clear. Acquired on-target and bypass resistance evidence also weakens confidence that ALK inhibition alone will remain sufficiently deep or durable across all tumors (C2-EV_TRACTABILITY_0007, C2-EV_BIOMARKER_0004).	Direct PK/PD exposure and target-engagement measurements in lung tumors and mucus-producing glandular cells for each small molecule. Target-turnover data and duration-of-inhibition requirements for EGFR and ALK in the specified cell type. Direct biodistribution data comparing intrapulmonary tumor exposure, normal lung exposure, and exposure in mucus-producing glandular cells. Evidence that the proposed compounds achieve sufficiently deep and sustained inhibition in the specified patient-derived xenograft context.	Several approved ALK TKIs ALK is clinically tractable with an established oral small-molecule kinase-inhibitor modality in metastatic NSCLC. First-line ALK inhibition produces strong systemic and intracranial clinical efficacy, supporting high tractability of ALK in NSCLC. Alectinib demonstrates that selective, CNS-penetrant ALK inhibition is an effective modality in treatment-naive advanced NSCLC. Multiple approved TKI generations The ALK small-molecule modality is vulnerable to acquired on-target resistance, particularly after sequential inhibitor treatment. ALK positivity does not ensure durable dependence on ALK signaling because resistance can arise through both on-target and off-target mechanisms.
MET — EGFR	Perturbational evidence	A wins	gpt-5.6-luna	94%	MET has explicit pharmacologic perturbation evidence in six MET-amplified lung-cancer PDX models showing antitumor responses, plus independent patient-derived EGFR-mutant/MET-amplified models responding to MET inhibition in vivo (C1-EV_PERTURBATION_0002, C1-EV_PERTURBATION_0003). The evidence is biomarker-restricted rather than universal, but that is consistent with the defined genomic-biomarker context. The EGFR dossier contains broad catalogue assertions about xenograft and PDX studies, but no comparably specific, model-level PDX result demonstrating reproducible disease-phenotype reversal. MET therefore has stronger reproducible perturbational evidence for this criterion.	A model-specific, reproducible EGFR perturbation study using patient-derived xenografts, with documented tumor regression or reversal of disease-relevant phenotypes and preferably orthogonal genetic and pharmacologic perturbations.	Pharmacologic MET inhibition suppresses MET-dependent lung cancer models in vitro and in vivo, with sensitivity linked to MET signaling complexes. A subset of EGFR-mutant, MET-amplified NSCLC models becomes dependent on MET and responds to MET inhibition alone. MET perturbational dependency in NSCLC is restricted to a molecularly defined subset rather than being general across lung cancer models. CRISPR MET knockout in A549 NSCLC cells did not materially impair intrinsic proliferation, despite reducing dissemination-related phenotypes.
EGFR — KRAS	Safety and essentiality	B wins	gpt-5.6-luna	79%	SECOND is modestly favoured. EGFR has broad normal epithelial function, severe knockout phenotypes, and explicit on-target dermatologic and gastrointestinal toxicity from wild-type inhibition (C1-EV_SAFETY_0001; C1-CAT-ONCO-BIO-052; C1-CAT-ONCO-BIO-054; C1-CAT-ONCO-BIO-098; C1-CAT-ONCO-BIO-102). KRAS is also broadly expressed and physiologically important, with embryonic knockout lethality and potential normal-tissue liabilities (C2-CAT-ONCO-BIO-047; C2-CAT-ONCO-BIO-052; C2-CAT-ONCO-BIO-054; C2-CAT-ONCO-BIO-114). However, the supplied safety evidence indicates that mutant-selective KRAS inhibitors can spare wild-type KRAS (C2-EV_SAFETY_0001), providing a more favourable anticipated profile for the stated small-molecule inhibition modality than non-mutant-selective EGFR inhibition. The margin is narrow because direct human safety, quantitative essentiality, PheWAS, and class-toxicology evidence are incomplete for both targets.	Direct comparative human LoF, pan-essentiality, PheWAS, and tissue-expression data for EGFR versus KRAS in lung mucus-producing glandular cells. A KRAS class-level small-molecule toxicology dataset, especially for inhibitors of KRAS G12D and non-G12C alleles. Quantitative human tissue-expression breadth and normal-tissue dependency data aligned to the specific KRAS inhibition modality.	On-target dermatologic and GI toxicity Ist EGFR üblicherweise essenziell? Ist EGFR für das Überleben oder die Proliferation von Krebszellen im Vergleich zu normalen Zellen essenziell? Welcher Phänotyp tritt auf, wenn EGFR deletiert wird? Welche Rolle spielt EGFR in gesunden Zellen/Geweben? Mutant-selective inhibitors spare wild type Ist KRAS üblicherweise essenziell? Ist KRAS für das Überleben oder die Proliferation von Krebszellen im Vergleich zu normalen Zellen essenziell? Welcher Phänotyp tritt auf, wenn KRAS deletiert wird? Welche Rolle spielt KRAS in gesunden Zellen/Geweben? In welchen krankheitsrelevanten Zelltypen wird KRAS exprimiert? Ist KRAS üblicherweise essenziell? Ist KRAS für das Überleben oder die Proliferation von Krebszellen im Vergleich zu normalen Zellen essenziell? Welche Gewebe oder Organsysteme sind bei der Maus nach dem Knockout des KRAS-Gens betroffen?
ALK — EGFR	Resistance and escape liability	A wins	gpt-5.6-luna	72%	Under the reversed criterion, ALK is judged less vulnerable, but only narrowly. ALK clearly has important escape liabilities: on-target compound mutations after sequential inhibitors, non-ALK-dependent resistance, subclonality, and bypass through EGFR/MAPK or redox-metabolic mechanisms (C1-EV_TRACTABILITY_0007, C1-EV_BIOMARKER_0004, C1-EV_TISSUE_0004, C1-EV_PERTURBATION_0002, C1-EV_PERTURBATION_0003). However, the dossier also supplies high-quality evidence that lorlatinib broadly inhibits evaluated single ALK resistance mutations and produces unusually durable systemic and intracranial control, supporting a comparatively more constrained and pharmacologically tractable escape landscape (C1-EV_COMPETITIVE_0004, C1-EV_CLINICAL_0004). EGFR likewise has acquired T790M and other target-site resistance, but the supplied evidence emphasizes a broad network of bypass and compensatory routes, including MET/HGF, alternative receptors, downstream pathway activation, clonal evolution, and intratumoral heterogeneity (C2-CAT-ONCO-BIO-004, C2-CAT-ONCO-BIO-013, C2-CAT-ONCO-BIO-063, C2-CAT-ONCO-BIO-066, C2-CAT-ONCO-BIO-067). Combination and biomarker strategies could mitigate risk for both: ALK resistance-genotype monitoring, variant-aware inhibitor selection, and pathway-directed combinations for identified bypasses; EGFR serial genotyping and MET/other bypass co-targeting. The dossiers do not establish that such combinations reduce resistance comparatively in clinical practice, so the advantage remains narrow.	A matched, prospective comparison of acquired resistance frequency, clonal diversity, and pathway-bypass mechanisms for biomarker-selected ALK- versus EGFR-driven NSCLC under contemporary first-line inhibitors, ideally with serial biopsies and ctDNA.	Lorlatinib has mechanistic differentiation through broad activity against single ALK kinase-domain resistance mutations, including G1202R, a major resistance mutation after earlier-generation ALK TKIs. Lorlatinib provides durable long-term clinical benefit in treatment-naive advanced ALK-positive NSCLC, with sustained systemic and intracranial disease control. The ALK small-molecule modality is vulnerable to acquired on-target resistance, particularly after sequential inhibitor treatment. ALK positivity does not ensure durable dependence on ALK signaling because resistance can arise through both on-target and off-target mechanisms. Genome-wide CRISPR knockout screens identify bypass alterations that permit survival under ALK inhibition, demonstrating context-dependent ALK-TKI dependence. Gibt es kompensatorische Mechanismen, die die Auswirkungen der Hemmung von EGFR abmildern können? Gibt es biochemische Signalwege, die die Hemmung von EGFR umgehen und dadurch zu einer Resistenz führen können? Ist EGFR von Resistenzmutationen betroffen? Gibt es Hinweise auf eine klonale Evolution unter Beteiligung von Veränderungen an EGFR während des Krankheitsverlaufs? CRISPR-Cas9 resistance screens show that KEAP1 loss modulates response to ALK inhibition in ALK-mutant lung cancer cells. Genome-wide CRISPR knockout identified MIG6/ERRFI1 loss as a mechanism of resistance to ALK TKIs through EGFR bypass signaling. ALK rearrangement is frequently subclonal or unevenly distributed across NSCLC tumor cells rather than present uniformly throughout the tumor. Competition is extending toward fourth-generation ALK inhibitors designed to address compound resistance mutations that can emerge after lorlatinib. Gibt es Hinweise auf genetische Heterogenität in EGFR innerhalb von Tumorpopulationen? Welche spezifischen genetischen Veränderungen in EGFR verleihen eine Resistenz gegen zielgerichtete Therapien oder Chemotherapie?
EGFR — ALK	Patient stratification	B wins	gpt-5.6-luna	93%	ALK supports the clearer prospectively testable selection hypothesis. ALK rearrangement is defined by an actionable molecular alteration, has FDA-authorized companion-diagnostic infrastructure, and was used to select patients in randomized clinical trials comparing ALK inhibition with chemotherapy. The genetic driver and its operational assay are therefore directly linked to prospective enrollment. EGFR has strong evidence for mutation-defined NSCLC subgroups and clinical targetability, but the supplied dossier is less direct about a single prospectively operationalized selection rule and relies more heavily on heterogeneous catalogue evidence. The ALK limitations—subclonality, nonproductive FISH results, and resistance—complicate interpretation but do not negate the feasibility of prospective ALK-positive selection.	A comparably direct prospective, biomarker-selected clinical validation package for EGFR mutation-defined NSCLC, including an explicitly specified assay and trial eligibility rule, would most challenge the preference for ALK.	ALK rearrangement is a validated predictive biomarker for ALK-targeted therapy in metastatic NSCLC. ALK-targeted therapy has an established companion-diagnostic infrastructure, supporting practical biomarker selection and deployment of the modality. ALK is clinically validated as a predictive therapeutic biomarker in advanced NSCLC by randomized phase 3 evidence showing superior efficacy of ALK inhibition over platinum-pemetrexed chemotherapy. A recurrent EML4–ALK fusion is a transforming somatic genetic alteration in human NSCLC. ALK rearrangements occur in a reproducible molecular subset of advanced NSCLC, enriched in younger and never-smoking patients. ALK positivity does not ensure durable dependence on ALK signaling because resistance can arise through both on-target and off-target mechanisms. ALK FISH positivity can represent a nonproductive rearrangement rather than an expressed, targetable ALK fusion. ALK rearrangement is frequently subclonal or unevenly distributed across NSCLC tumor cells rather than present uniformly throughout the tumor.
EGFR — KRAS	Competitive differentiation	B wins	gpt-5.6-luna	78%	KRAS offers the stronger mechanism-implied differentiation: KRAS-G12C creates a mutation-associated covalent binding opportunity, and the dossier states that mutant-selective inhibitors can spare wild-type KRAS (C2-CAT-ONCO-BIO-091b; C2-CAT-ONCO-BIO-064), with clinically validated small-molecule tractability (C2-EV_TRACTABILITY_0001). By contrast, EGFR has multiple approved small-molecule TKI generations (C1-EV_TRACTABILITY_0001), while wild-type EGFR inhibition produces on-target dermatologic and gastrointestinal toxicity (C1-EV_SAFETY_0001), reducing the implied differentiation over chemotherapy. This is a scientific and mechanism-based differentiation judgment, not a market-attractiveness judgment. The margin is narrow because KRAS-G12C is itself clinically established and described as an active research field with ongoing resistance and combination challenges (C2-CAT-ONCO-BIO-088), while the dossiers lack direct first-line, chemotherapy-backbone comparative evidence.	Direct clinical evidence in newly diagnosed NSCLC comparing each target-directed strategy, combined with chemotherapy, against chemotherapy alone. A defined competitor-pipeline comparison for the proposed EGFR and KRAS small molecules, including differentiation by allele coverage, resistance profile, safety, and first-line positioning.	Ist ein mutationsspezifisches Targeting von KRAS realisierbar? Ist die Beeinträchtigung der Funktion von KRAS selektiv? Clinically validated tractability Multiple approved TKI generations On-target dermatologic and GI toxicity Wie ist der aktuelle Stand der Forschung zu KRAS? Wie ist der aktuelle Stand der Forschung zu EGFR?
ALK — MET	Combination potential	Abstained	gpt-5.6-luna	98%	The dossiers provide substantial evidence for ALK and MET monotherapy dependence, resistance mechanisms, and individual-agent toxicities, but they do not provide direct evidence of combination with chemotherapy. ALK resistance evidence concerns EGFR/MAPK, PI3K/AKT, KEAP1, or on-target ALK mechanisms (C1-EV_PERTURBATION_0002, C1-EV_PERTURBATION_0003, C1-EV_PERTURBATION_0005), while MET combination evidence concerns EGFR inhibition rather than chemotherapy (C2-EV_MECHANISM_0004, C2-EV_MECHANISM_0005). Individual toxicity evidence exists for ALK (C1-EV_SAFETY_0005, C1-EV_SAFETY_0006, C1-EV_SAFETY_0007) and MET (C2-EV_SAFETY_0004, C2-EV_SAFETY_0006, C2-EV_SAFETY_0007), but no overlapping-toxicity or combination-dosing assessment is supplied. Because mechanistic non-redundancy alone is insufficient and the required chemotherapy-combination evidence is missing, ranking one target would be unsupported.	Direct ALK-plus-chemotherapy and MET-plus-chemotherapy combination preclinical studies in NSCLC, including pathway-complementarity and resistance-mechanism analyses. Formal overlapping-toxicity, dose-exposure, and tolerability assessments for combining each target inhibitor with chemotherapy. Comparative in vivo combination efficacy and safety data in the specified patient-derived xenograft context.	–
EGFR — KRAS	Combination potential	Abstained	gpt-5.6-luna	98%	Neither dossier supplies direct evidence for combination with chemotherapy in NSCLC that satisfies the criterion. The EGFR dossier documents on-target rash and diarrhoea, indicating a potential combination safety constraint (C1-EV_SAFETY_0001), while the KRAS dossier states that mutant-selective inhibitors spare wild-type KRAS but does not assess combined dosing or chemotherapy toxicity (C2-EV_SAFETY_0001). Mechanistic target biology and general resistance information are insufficient under the guardrail without combination studies and overlapping-toxicity assessment. Therefore, there is not enough admissible evidence to compare the candidates.	Direct chemotherapy-combination preclinical studies for each target in NSCLC, including pathway-complementarity or resistance-mechanism data, and a comparative overlapping-toxicity/dose-schedule assessment.	On-target dermatologic and GI toxicity Mutant-selective inhibitors spare wild type
ALK — MET	Safety and essentiality	Abstained	gpt-5.6-luna	93%	Both targets have clinical class-toxicity evidence, but these data do not establish a clean comparative on-target safety advantage: ALK has a mouse knockout suggesting limited broad essentiality but also reproductive and neuroendocrine phenotypes, while ALK inhibitors show clinically important organ toxicities. MET has a general manageable-profile claim but also edema, interstitial lung disease, hepatic, pancreatic, and embryo-fetal toxicities. The MET dossier lacks the human LoF, pan-essentiality, normal-tissue expression-breadth, and knockout evidence needed to interpret that absence as safety. Because the key comparative on-target evidence is incomplete and molecule/modality effects are entangled, ranking either target would violate the understudied-target guardrail.	Human loss-of-function phenotype data, pan-essentiality scores, and systematic normal-tissue expression breadth for MET comparable to the ALK knockout evidence. Direct comparative on-target safety evidence separating target-mediated effects from molecule-specific and modality-specific toxicities for the ALK and MET inhibitor classes. Human genetic loss-of-function and normal-tissue knockout data for both targets; the supplied ALK knockout evidence is from mice and the MET dossier lacks comparable normal-tissue knockout evidence.	Favourable on-target safety Wild-type ALK appears to have limited essentiality for survival of adult normal tissues, although loss of ALK produces specific reproductive and neuroendocrine phenotypes in mice. ALK inhibition has a generally manageable clinical safety profile but carries clinically important risks, including hepatotoxicity, interstitial lung disease/pneumonitis, QT prolongation, bradycardia, severe visual loss, and embryo-fetal toxicity. Alectinib has clinically important hepatotoxicity and other organ toxicities that complicate the safety case for ALK inhibition. First-line lorlatinib produces a high burden of metabolic, neurologic and other adverse events, with more grade 3–4 toxicity than crizotinib. Manageable on-target profile Clinical targeting of MET has substantial but monitorable toxicity, including edema, interstitial lung disease, hepatotoxicity, pancreatic toxicity, and embryo-fetal toxicity. A second selective MET inhibitor confirms both target dependence and a clinically relevant toxicity burden in MET exon 14–skipping NSCLC. Tepotinib has clinically important, potentially fatal pulmonary toxicity in MET-altered NSCLC. Tepotinib safety includes hepatotoxicity, pancreatic enzyme elevations and embryo-fetal toxicity requiring monitoring or treatment modification. Wild-type ALK appears to have limited essentiality for survival of adult normal tissues, although loss of ALK produces specific reproductive and neuroendocrine phenotypes in mice. ALK inhibition has a generally manageable clinical safety profile but carries clinically important risks, including hepatotoxicity, interstitial lung disease/pneumonitis, QT prolongation, bradycardia, severe visual loss, and embryo-fetal toxicity. Alectinib has clinically important hepatotoxicity and other organ toxicities that complicate the safety case for ALK inhibition. First-line lorlatinib produces a high burden of metabolic, neurologic and other adverse events, with more grade 3–4 toxicity than crizotinib. Clinical targeting of MET has substantial but monitorable toxicity, including edema, interstitial lung disease, hepatotoxicity, pancreatic toxicity, and embryo-fetal toxicity. A second selective MET inhibitor confirms both target dependence and a clinically relevant toxicity burden in MET exon 14–skipping NSCLC. Tepotinib has clinically important, potentially fatal pulmonary toxicity in MET-altered NSCLC. Tepotinib safety includes hepatotoxicity, pancreatic enzyme elevations and embryo-fetal toxicity requiring monitoring or treatment modification.
EGFR — ALK	Translational model validity	B wins	gpt-5.6-luna	91%	ALK has the stronger translational-model evidence. Its dossier supplies specific perturbational efficacy in EML4-ALK-positive NSCLC models including a patient-derived NSCLC cell line, genetically engineered mouse models producing lung tumors, and human cancer-cell validation, with additional randomized evidence in previously untreated ALK-positive NSCLC supporting clinical relevance. EGFR has strong biological and target-validation evidence, including described transgenic mouse and PDX applications, but the supplied dossier does not provide comparably specific, independently documented efficacy results from human organoids, primary patient cells, humanised models, or ex vivo tissue. The ALK evidence is therefore more directly tied to mechanistically and clinically relevant NSCLC models, despite documented heterogeneity of ALK dependence and fusion-variant sensitivity.	Directly comparable EGFR and ALK efficacy studies in matched patient-derived models or human organoids from newly diagnosed NSCLC, including the specified mucus-producing glandular cell context. For EGFR, a specific peer-reviewed efficacy result in a patient-derived, primary-human, humanised, or ex vivo NSCLC model is not supplied; the dossier mainly provides general model descriptions and catalogue summaries.	Direct ALK knockdown selectively impairs viability and clonogenic growth of EML4-ALK-positive NSCLC cells. Alveolar epithelial cells can serve as a relevant lung cellular context for EML4–ALK-driven tumorigenesis in vivo. The EML4 portion of EML4-ALK promotes cytoplasmic phase-separated condensates that organize downstream signaling, including STAT3 activation, and support lung tumorigenesis. ALK is clinically validated as a predictive therapeutic biomarker in advanced NSCLC by randomized phase 3 evidence showing superior efficacy of ALK inhibition over platinum-pemetrexed chemotherapy. Second-generation ALK inhibition provides superior systemic and intracranial disease control compared with first-generation therapy in untreated advanced ALK-positive NSCLC. ALK rearrangement does not uniformly establish ALK pathway dependence across NSCLC models. ALK fusion variants produce materially different pathway dependency and inhibitor sensitivity. ALK rearrangement is frequently subclonal or unevenly distributed across NSCLC tumor cells rather than present uniformly throughout the tumor. CRISPR-based in vivo perturbation shows that EML4-ALK variants are functionally heterogeneous rather than a uniform dependency context.
ALK — KRAS	Evidence robustness (meta-evidence)	A wins	gpt-5.6-luna	88%	ALK has a comparatively transparent multi-source package: peer-reviewed discovery and genomic cohorts, real-world prevalence data, multiple randomized clinical trials, and explicitly reported contradictory or negative findings such as incomplete pathway dependence, variant-specific sensitivity, subclonality, and lack of unadjusted overall-survival benefit. These limitations make the package more auditable and resilient to publication bias than a uniformly positive dossier. KRAS includes some independent human-genomics cohorts and acknowledges context dependence, but most of its material consists of catalogue-style answers without explicit provenance, replication, overlap, or negative-result metadata; the dossier therefore provides weaker meta-evidence for source independence and robustness. The judgment is based on evidence structure and contradiction handling, not on the larger number of ALK items.	For KRAS, explicit provenance metadata, source-family structure, cohort-overlap assessment, independent replication status, and systematically reported negative results for direct KRAS perturbation in the stated NSCLC/P DX context. For both candidates, a formal study-level evidence map identifying which reports share cohorts, models, investigators, or underlying trials.	A recurrent EML4–ALK fusion is a transforming somatic genetic alteration in human NSCLC. Independent comprehensive tumor-genome profiling confirms ALK rearrangements as recurrent somatic driver events in lung adenocarcinoma. ALK rearrangements occur in a reproducible molecular subset of advanced NSCLC, enriched in younger and never-smoking patients. ALK is clinically validated as a predictive therapeutic biomarker in advanced NSCLC by randomized phase 3 evidence showing superior efficacy of ALK inhibition over platinum-pemetrexed chemotherapy. Second-generation ALK inhibition provides superior systemic and intracranial disease control compared with first-generation therapy in untreated advanced ALK-positive NSCLC. Brigatinib demonstrated superior first-line efficacy, including intracranial activity, versus crizotinib in ALK-positive advanced NSCLC. Lorlatinib provides durable long-term clinical benefit in treatment-naive advanced ALK-positive NSCLC, with sustained systemic and intracranial disease control. ALK rearrangement does not uniformly establish ALK pathway dependence across NSCLC models. ALK fusion variants produce materially different pathway dependency and inhibitor sensitivity. ALK rearrangement does not uniformly establish ALK pathway dependence across NSCLC models. ALK fusion variants produce materially different pathway dependency and inhibitor sensitivity. ALK rearrangement is frequently subclonal or unevenly distributed across NSCLC tumor cells rather than present uniformly throughout the tumor. The pivotal PROFILE 1014 trial did not demonstrate a statistically significant overall-survival benefit for first-line crizotinib in the unadjusted analysis. Ist KRAS üblicherweise essenziell? Welche Folgen hat der Knockdown oder Knockout von KRAS in verschiedenen Zelltypen?
KRAS — EGFR	Translational model validity	B wins	gpt-5.6-luna	90%	EGFR has direct evidence in mechanistically relevant EGFR-mutant lung adenocarcinoma GEMMs, including response to EGFR inhibition, and the dossier also identifies NSCLC xenograft, PDX, and other translational models. KRAS has general statements that NSCLC PDX and CDX studies exist, but the specifically described efficacy result is from a subcutaneous MiaPaCa-2 human xenograft rather than an NSCLC model. Thus EGFR provides stronger model-validity evidence for NSCLC; this judgment is based on model relevance rather than reported effect size.	A directly comparable KRAS NSCLC efficacy dataset in validated lung GEMM, orthotopic, humanised, or patient-derived models, with explicit relevance to newly diagnosed disease and chemotherapy combination.	Welche Tiermodelle validieren EGFR? Welche Ergebnisse wurden in den einzelnen Tiermodellen mit EGFR erzielt? Gibt es veröffentlichte Studien, in denen die verfügbaren Tool-Substanzen zur Validierung von EGFR in präklinischen Modellen eingesetzt wurden? Welche Ergebnisse wurden in den einzelnen Tiermodellen mit KRAS erzielt? Gibt es veröffentlichte Studien, in denen die verfügbaren Tool-Substanzen zur Validierung von KRAS in präklinischen Modellen eingesetzt wurden?
KRAS — ALK	Safety and essentiality	B wins	gpt-5.6-luna	82%	ALK has the more favourable anticipated on-target profile because the dossier reports narrow adult expression and viable homozygous kinase-domain knockout mice, with specific but limited reproductive and neuroendocrine phenotypes (C2-EV_SAFETY_0001, C2-EV_SAFETY_0004). KRAS is broadly expressed and physiologically important; complete loss is embryonically lethal in mice and affects hematopoiesis, although mutant-selective inhibitors can spare wild-type KRAS (C1-CAT-ONCO-BIO-047, C1-CAT-ONCO-BIO-052, C1-CAT-ONCO-BIO-054, C1-CAT-ONCO-BIO-114, C1-EV_SAFETY_0001). The margin is narrow because ALK inhibitor clinical toxicities are documented, but these may be molecule- or modality-specific rather than evidence of ALK on-target essentiality (C2-EV_SAFETY_0005, C2-EV_SAFETY_0006, C2-EV_SAFETY_0007).	Direct human LoF or PheWAS comparisons for KRAS versus ALK, quantitative pan-essentiality scores, and tissue-expression breadth data measured on a comparable basis for both targets	Favourable on-target safety Wild-type ALK appears to have limited essentiality for survival of adult normal tissues, although loss of ALK produces specific reproductive and neuroendocrine phenotypes in mice. In welchen krankheitsrelevanten Zelltypen wird KRAS exprimiert? Ist KRAS üblicherweise essenziell? Ist KRAS für das Überleben oder die Proliferation von Krebszellen im Vergleich zu normalen Zellen essenziell? Welche Gewebe oder Organsysteme sind bei der Maus nach dem Knockout des KRAS-Gens betroffen? Mutant-selective inhibitors spare wild type ALK inhibition has a generally manageable clinical safety profile but carries clinically important risks, including hepatotoxicity, interstitial lung disease/pneumonitis, QT prolongation, bradycardia, severe visual loss, and embryo-fetal toxicity. Alectinib has clinically important hepatotoxicity and other organ toxicities that complicate the safety case for ALK inhibition. First-line lorlatinib produces a high burden of metabolic, neurologic and other adverse events, with more grade 3–4 toxicity than crizotinib.
KRAS — MET	Clinical validation	B wins	gpt-5.6-luna	97%	MET has substantially stronger indication-relevant clinical validation in NSCLC: genotype-selected phase 2 trials demonstrated durable responses to selective MET inhibitors, with traditional FDA approvals for MET exon 14–skipping disease and prospective molecular pharmacodynamic evidence linking METex14 depletion to response (C2-EV_CLINICAL_0001, C2-EV_CLINICAL_0002, C2-EV_CLINICAL_0003, C2-EV_BIOMARKER_0001, C2-EV_BIOMARKER_0002). The dossier also includes a validated pMET target-engagement assay (C2-EV_BIOMARKER_0005). MET amplification is weaker and threshold-dependent, and broad MET or IHC-selected strategies had negative trials (C2-EV_CLINICAL_0006, C2-EV_BIOMARKER_0004, C2-EV_MECHANISM_0006, C2-EV_MECHANISM_0007), but these limitations do not negate the strong METex14 evidence. KRAS has evidence of approved mutant-selective inhibitors and clinical tractability (C1-EV_TRACTABILITY_0001, C1-CAT-ONCO-BIO-091b), yet lacks a comparably detailed, indication-specific clinical validation dataset in the supplied dossier. The advantage is therefore clear, while not establishing superiority for the exact newly diagnosed chemotherapy context.	An indication-matched, head-to-head comparison of KRAS-directed therapy versus MET-directed therapy in newly diagnosed NSCLC receiving chemotherapy, including randomized design, dose, pharmacokinetic exposure, target engagement, and clinically relevant endpoints. Direct KRAS NSCLC clinical-trial evidence with comparable detail on patient selection, response durability, target engagement, and dose/exposure; the KRAS dossier mainly supplies approval and tractability claims without a comparable trial dataset.	MET exon 14 skipping is clinically validated as a predictive biomarker in metastatic NSCLC through durable responses to selective MET inhibitors. Tepotinib has traditional FDA approval for metastatic NSCLC harboring MET exon 14 skipping alterations, with efficacy confirmed in a 313-patient dataset. Capmatinib is FDA-indicated for metastatic NSCLC with a mutation leading to MET exon 14 skipping, selected using an FDA-approved test. MET exon 14 skipping is a clinically validated predictive biomarker for selective MET inhibition in NSCLC. Serial depletion of METex14 ctDNA is an on-treatment pharmacodynamic biomarker associated with clinical response to tepotinib. Validated pharmacodynamic assays based on the pMET:total-MET ratio provide a direct biochemical readout of MET pathway inhibition and are suitable for target-engagement studies. Capmatinib produced substantial responses in MET exon 14–skipping NSCLC, providing direct clinical proof of target tractability for this biomarker-defined subgroup. A second selective oral MET inhibitor, tepotinib, has demonstrated sufficient efficacy for traditional approval in MET exon 14–skipping metastatic NSCLC. MET amplification has weaker and threshold-dependent clinical validation than MET exon 14 skipping in NSCLC. MET immunohistochemistry did not identify patients who benefited from onartuzumab in the randomized phase III METLung trial. MET immunohistochemical positivity did not identify a clinically responsive NSCLC population in the phase III METLung trial. Adding the MET inhibitor tivantinib to erlotinib failed to improve overall survival in the phase III ATTENTION trial.
MET — ALK	Biomarker and target engagement	B wins	gpt-5.6-luna	88%	Both targets have credible biomarker strategies. MET has strong regulatory validation for MET exon 14 skipping, prospective tissue/plasma selection, serial METex14 ctDNA depletion associated with response, and a fit-for-clinic pMET:total-MET pharmacodynamic assay (C1-EV_BIOMARKER_0001, C1-EV_BIOMARKER_0002, C1-EV_BIOMARKER_0005, C1-EV_CLINICAL_0003). However, its early efficacy evidence is primarily phase 2 and biomarker interpretation is complicated by assay discordance and heterogeneity (C1-EV_BIOMARKER_0006). ALK has FDA-authorized companion-diagnostic infrastructure, randomized first-line evidence versus platinum-pemetrexed chemotherapy in centrally confirmed ALK-positive disease, and longitudinal plasma mutation kinetics consistent with on-target inhibition (C2-EV_TRACTABILITY_0006, C2-EV_BIOMARKER_0002, C2-EV_BIOMARKER_0005, C2-EV_CLINICAL_0001). Although FISH can occasionally detect nonproductive rearrangements and ALK positivity does not guarantee durable dependence, the overall clinical selection and early efficacy framework is more mature and directly demonstrated for ALK. The margin is narrow because MET has particularly strong prospective ctDNA pharmacodynamic evidence and a direct biochemical engagement assay.	A prospective randomized first-line METex14-selected NSCLC trial directly comparing MET inhibition with chemotherapy, together with a clinically established target-engagement assay linked to early efficacy, would most change the comparison.	ALK rearrangement is a validated predictive biomarker for ALK-targeted therapy in metastatic NSCLC. In untreated advanced ALK-positive NSCLC, biomarker-selected patients derived substantially greater benefit from ALK inhibition with crizotinib than from platinum-pemetrexed chemotherapy. ALK-targeted therapy has an established companion-diagnostic infrastructure, supporting practical biomarker selection and deployment of the modality. Longitudinal plasma ALK mutation kinetics provide pharmacodynamic evidence consistent with on-target ALK inhibition by lorlatinib. ALK is clinically validated as a predictive therapeutic biomarker in advanced NSCLC by randomized phase 3 evidence showing superior efficacy of ALK inhibition over platinum-pemetrexed chemotherapy. MET exon 14 skipping is a clinically validated predictive biomarker for selective MET inhibition in NSCLC. Serial depletion of METex14 ctDNA is an on-treatment pharmacodynamic biomarker associated with clinical response to tepotinib. Validated pharmacodynamic assays based on the pMET:total-MET ratio provide a direct biochemical readout of MET pathway inhibition and are suitable for target-engagement studies. Capmatinib is FDA-indicated for metastatic NSCLC with a mutation leading to MET exon 14 skipping, selected using an FDA-approved test. ALK FISH positivity can represent a nonproductive rearrangement rather than an expressed, targetable ALK fusion. ALK positivity does not ensure durable dependence on ALK signaling because resistance can arise through both on-target and off-target mechanisms. MET immunohistochemistry did not identify patients who benefited from onartuzumab in the randomized phase III METLung trial. MET biomarker classification is substantially affected by intratumoral heterogeneity and discordance between assays.
MET — KRAS	Novelty, crowding, and strategic optionality	A wins	gpt-5.6-luna	72%	MET has the stronger documented strategic-optionality case: it supports genotype-selected small-molecule inhibition and a distinct ADC modality, with clinically actionable MET exon 14 and high c-MET-overexpression segments. However, the MET class is explicitly crowded by multiple approved or clinically active inhibitors and a non-TKI competitor. That crowding increases biological confidence but reduces differentiation and strategic value. KRAS has meaningful allelic and modality-expansion potential, particularly from clinically validated G12C toward other KRAS variants, but the dossier does not provide a comparable phase-specific competitor pipeline, direct indication-expansion evidence, or patent-landscape evidence. Therefore MET ranks narrowly on documented optionality, while the absence of KRAS crowding evidence is treated as missing information rather than evidence of lower competition.	A phase-specific KRAS competitor pipeline in NSCLC, including G12C, G12D and other allele-specific programs Comparative patent-landscape evidence for MET versus KRAS Direct evidence of KRAS indication expansion or platform leverage beyond general catalogue descriptions	MET is clinically tractable in NSCLC through genotype-selected, oral small-molecule kinase inhibition of MET exon 14–skipping tumors. A second selective oral MET inhibitor, tepotinib, has demonstrated sufficient efficacy for traditional approval in MET exon 14–skipping metastatic NSCLC. MET is tractable with an antibody–drug conjugate modality for a distinct biomarker-defined NSCLC population characterized by high c-Met protein overexpression. High c-MET protein overexpression represents a second clinically actionable MET biomarker context in nonsquamous NSCLC, although the regulatory evidence is based on accelerated approval. The METex14 NSCLC market is already competitive, with multiple approved or clinically active MET inhibitors rather than a single differentiated standard. MET-targeted competition now includes a non-TKI modality with a broader MET-overexpression biomarker strategy. Clinically validated tractability Weist KRAS Mutationen auf, die neue medikamentös adressierbare Bindungsstellen schaffen? Wie ist der aktuelle Stand der Forschung zu KRAS? The METex14 NSCLC market is already competitive, with multiple approved or clinically active MET inhibitors rather than a single differentiated standard. MET-targeted competition now includes a non-TKI modality with a broader MET-overexpression biomarker strategy.
ALK — EGFR	Cell and tissue relevance	A wins	gpt-5.6-luna	77%	FIRST has stronger, more direct human tissue evidence: ALK rearrangement was detected by FISH and confirmed by ALK immunohistochemistry in NSCLC tumor tissue, with localization to pulmonary adenocarcinoma epithelial cells (C1-EV_TISSUE_0002; C1-EV_TISSUE_0006). SECOND has evidence that EGFR is expressed or overexpressed in malignant epithelial cells and NSCLC, but the supplied evidence is broad and does not localize EGFR specifically to mucus-producing glandular cells (C2-CAT-ONCO-BIO-047; C2-CAT-ONCO-BIO-058). The margin is narrow because neither dossier provides direct single-cell or spatial evidence for the specified mucus-producing glandular cell type, and ALK is reported as subclonal and histologically heterogeneous, limiting a uniform dysregulation claim (C1-EV_TISSUE_0004; C1-EV_TISSUE_0005).	Direct single-cell or spatial profiling, preferably with cell-composition and disease-stage controls, demonstrating ALK or EGFR dysregulation specifically in mucus-producing glandular cells of human NSCLC. Direct comparative immunohistochemistry or proteomics for ALK versus EGFR in mucus-producing glandular tumor cells.	ALK rearrangements are directly detectable in lung adenocarcinoma tumor tissue and are associated with ALK protein expression in the tumor cells. ALK-positive NSCLC is most strongly represented in the lung adenocarcinoma epithelial compartment, with frequent pulmonary adenocarcinoma markers and characteristic tumor-cell morphology. In welchen krankheitsrelevanten Zelltypen wird EGFR exprimiert? Wird EGFR in krankheitsrelevanten Zelltypen überexprimiert? ALK rearrangement is frequently subclonal or unevenly distributed across NSCLC tumor cells rather than present uniformly throughout the tumor. ALK-rearranged lung carcinomas can contain mixed histologic and cellular differentiation, so morphology alone does not define a single ALK-associated tissue or cell type.
ALK — KRAS	Cell and tissue relevance	Abstained	gpt-5.6-luna	98%	Neither dossier provides direct evidence in the specified critical cell type, mucus-producing glandular cells. ALK is localized broadly to malignant pulmonary epithelial/adenocarcinoma cells by tissue pathology, while KRAS is described as broadly expressed with relevance driven mainly by mutations rather than overexpression. These findings do not establish cell-specific expression, localization, or dysregulation in mucus-producing glandular cells, nor do they control for composition shifts or disease stage. Therefore the criterion cannot be compared.	Single-cell or spatial transcriptomics, proteomics, or cell-resolved immunohistochemistry in human NSCLC specifically localizing ALK or mutant KRAS expression, protein, and dysregulation to mucus-producing glandular cells, with adjustment for cell-composition shifts and disease stage.	ALK rearrangements are directly detectable in lung adenocarcinoma tumor tissue and are associated with ALK protein expression in the tumor cells. ALK-positive NSCLC is most strongly represented in the lung adenocarcinoma epithelial compartment, with frequent pulmonary adenocarcinoma markers and characteristic tumor-cell morphology. In welchen krankheitsrelevanten Zelltypen wird KRAS exprimiert? Wird KRAS in krankheitsrelevanten Zelltypen überexprimiert?
KRAS — EGFR	Cell and tissue relevance	Abstained	gpt-5.6-luna	98%	Neither dossier provides criterion-specific evidence in the critical mucus-producing glandular cell type. KRAS evidence describes broad/near-ubiquitous expression and mutation prevalence (C1-CAT-ONCO-BIO-047, C1-CAT-ONCO-BIO-058), while EGFR evidence describes expression in broad malignant epithelial populations and NSCLC generally (C2-CAT-ONCO-BIO-047, C2-CAT-ONCO-BIO-058). These do not establish comparative expression, localisation, or dysregulation in mucus-producing glandular cells, nor do they control for cell-composition shifts or disease stage. Therefore the dossiers do not contain the evidence required to rank the candidates.	Single-cell or spatial transcriptomic, proteomic, immunohistochemical, or human-pathology evidence directly measuring KRAS versus EGFR expression, subcellular localisation, and dysregulation in lung mucus-producing glandular cells in NSCLC, with adjustment for cell-composition shifts and disease stage.	–
EGFR — MET	Novelty, crowding, and strategic optionality	B wins	gpt-5.6-luna	78%	MET offers greater documented strategic optionality because the dossier supports multiple clinically actionable biomarker contexts and modalities: MET exon 14 skipping and amplification are addressed with small-molecule inhibitors, while high c-MET overexpression supports an ADC strategy (C2-EV_TRACTABILITY_0002, C2-EV_TRACTABILITY_0005, C2-EV_CLINICAL_0004). However, the METex14 segment is already crowded with multiple approved or clinically active inhibitors and a non-TKI competitor, which reduces differentiation despite increasing biological validation (C2-EV_COMPETITIVE_0005, C2-EV_COMPETITIVE_0006). EGFR has evidence of broad oncology relevance and multiple target-engagement approaches, but this dossier lacks a directly comparable EGFR competitor-pipeline or patent-landscape assessment. Therefore SECOND is favored, but narrowly rather than clearly.	A directly comparable competitor-pipeline analysis for EGFR in NSCLC, including phase, indication, modality, and differentiation. Patent-landscape and freedom-to-operate evidence for both EGFR and MET. Direct evidence comparing indication-expansion potential and platform leverage of EGFR versus MET outside the presented NSCLC contexts.	MET is clinically tractable in NSCLC through genotype-selected, oral small-molecule kinase inhibition of MET exon 14–skipping tumors. MET is tractable with an antibody–drug conjugate modality for a distinct biomarker-defined NSCLC population characterized by high c-Met protein overexpression. High c-MET protein overexpression represents a second clinically actionable MET biomarker context in nonsquamous NSCLC, although the regulatory evidence is based on accelerated approval. The METex14 NSCLC market is already competitive, with multiple approved or clinically active MET inhibitors rather than a single differentiated standard. MET-targeted competition now includes a non-TKI modality with a broader MET-overexpression biomarker strategy. The METex14 NSCLC market is already competitive, with multiple approved or clinically active MET inhibitors rather than a single differentiated standard. MET-targeted competition now includes a non-TKI modality with a broader MET-overexpression biomarker strategy. MET amplification has weaker and threshold-dependent clinical validation than MET exon 14 skipping in NSCLC. Broad MET amplification is less reliably tractable than MET exon 14 skipping and requires biomarker refinement, particularly regarding amplification level.
KRAS — EGFR	Human genetics and causal evidence	A wins	gpt-5.6-luna	75%	Both candidates have direct human tumor-genomics evidence for activating somatic mutations with a causal-driver interpretation. KRAS has broader supporting evidence across multiple human NSCLC/lung adenocarcinoma cohorts, including recurrence with an allelic series and replicated prevalence/driver observations. EGFR has a strong but less fully documented summary claim for causal Exon-19 deletions and L858R. Neither dossier supplies GWAS, fine-mapping, L2G, molecular-QTL colocalisation, rare-variant burden, or ancestry-diverse evidence, so the comparison is narrow rather than clear.	GWAS or fine-mapping with variant-to-gene or L2G assignment for either candidate Molecular-QTL colocalisation with NSCLC-relevant traits and tissues Rare-variant burden or biobank phenotype analyses Explicit ancestry-diverse replication and cohort-level details for the EGFR causal claims	Recurrent activating mutations KRAS is a recurrent, activating somatic driver in human lung adenocarcinoma, supporting KRAS inhibition as a genetically defined therapeutic strategy in NSCLC. Independent prospective clinical sequencing confirms KRAS as one of the dominant oncogenic drivers in metastatic human lung adenocarcinoma. KRAS mutations are common in human NSCLC, particularly lung adenocarcinoma, with KRAS G12C representing the largest mutation subtype and a genetically defined inhibitor-sensitive population. Causal activating mutations
EGFR — MET	Druggability and tractability	A wins	gpt-5.6-luna	84%	Both targets have strong small-molecule precedent. EGFR has multiple approved TKI generations, available research tools, and dossier evidence that activating mutations alter the kinase conformation and enable mutant-selective inhibitor binding. MET also has clinically validated oral TKIs and PDX evidence, particularly for MET exon 14 skipping, but tractability is more dependent on the precise alteration and amplification level; low-level amplification and protein-expression-based selection are less reliable. The advantage for EGFR is therefore narrow, driven by broader small-molecule precedent and more explicit binding-site/selectivity evidence, not by evidence of superior lung delivery.	Head-to-head experimental or predicted structures with pocket-quality metrics for EGFR and MET Comparative small-molecule exposure and target-engagement data in lung mucus-producing glandular cells or matched PDX tissue Direct comparative evidence on protein turnover and selectivity margins in the specified lung context	Multiple approved TKI generations Weist EGFR Mutationen auf, die neue medikamentös adressierbare Bindungsstellen schaffen? Verändern Mutationen in EGFR bestehende medikamentös adressierbare Stellen? Welche Toolverbindungen für EGFR sind verfügbar? MET is clinically tractable in NSCLC through genotype-selected, oral small-molecule kinase inhibition of MET exon 14–skipping tumors. Capmatinib produced substantial responses in MET exon 14–skipping NSCLC, providing direct clinical proof of target tractability for this biomarker-defined subgroup. A second selective oral MET inhibitor, tepotinib, has demonstrated sufficient efficacy for traditional approval in MET exon 14–skipping metastatic NSCLC. On-target dermatologic and GI toxicity Clinical targeting of MET has substantial but monitorable toxicity, including edema, interstitial lung disease, hepatotoxicity, pancreatic toxicity, and embryo-fetal toxicity. Tepotinib has clinically important, potentially fatal pulmonary toxicity in MET-altered NSCLC. Broad MET amplification is less reliably tractable than MET exon 14 skipping and requires biomarker refinement, particularly regarding amplification level.
MET — EGFR	Human natural experiments	Abstained	gpt-5.6-luna	91%	Neither dossier supplies a qualifying human natural experiment demonstrating both efficacy and tolerability for inhibition. MET has somatic gain-of-function driver evidence and clinical pharmacological responses, but these are not biobank/Mendelian/protective-allele or long-term-exposure natural experiments; its drug evidence also documents substantial toxicity. EGFR has germline loss-of-function disease phenotypes and rare germline gain-of-function predisposition, but lifetime genetic exposure is not equivalent to time-limited pharmacological inhibition, and the supplied germline evidence does not demonstrate NSCLC treatment efficacy. EGFR pharmacological efficacy and on-target toxicity are presented, but not as the specified natural-experiment evidence. Therefore the criterion cannot distinguish the candidates.	A human biobank loss-of-function or protective-allele study, Mendelian disease analysis, or long-term drug-exposure cohort for each target that directly links the therapeutic inhibition direction to both NSCLC efficacy and tolerability.	TCGA-integrated human tumor sequencing identified recurrent somatic MET exon 14 skipping as a likely driver alteration in lung adenocarcinoma. MET exon 14–altered NSCLC shows clinically meaningful dependence on MET signaling, supporting MET as an essential therapeutic driver in this molecular subset. Clinical targeting of MET has substantial but monitorable toxicity, including edema, interstitial lung disease, hepatotoxicity, pancreatic toxicity, and embryo-fetal toxicity. Causal activating mutations Gibt es genetische Erkrankungen, die mit EGFR in Verbindung stehen? Gibt es Erkrankungen, die mit genetischen Keimbahnveränderungen von EGFR assoziiert sind? On-target dermatologic and GI toxicity Clinical targeting of MET has substantial but monitorable toxicity, including edema, interstitial lung disease, hepatotoxicity, pancreatic toxicity, and embryo-fetal toxicity. Tepotinib has clinically important, potentially fatal pulmonary toxicity in MET-altered NSCLC. Gibt es genetische Erkrankungen, die mit EGFR in Verbindung stehen? Ist EGFR in der Keimbahn genetisch verändert? On-target dermatologic and GI toxicity
EGFR — KRAS	Novelty, crowding, and strategic optionality	B wins	gpt-5.6-luna	68%	KRAS has the stronger, though narrow, strategic-optionality signal because the dossier describes a mutation-spanning small-molecule platform: clinically validated G12C targeting, active expansion toward G12D/G12V and pan-KRAS/pan-RAS strategies, and additional alternative binding sites (C2-CAT-ONCO-BIO-088, C2-CAT-ONCO-BIO-091b, C2-CAT-ONCO-BIO-023). It also has relevance across NSCLC, colorectal, pancreatic, and other solid tumors (C2-CAT-ONCO-BIO-046). EGFR likewise has substantial optionality through multiple indications, mutations, binding sites, antibodies, and TKIs (C1-CAT-ONCO-BIO-046, C1-CAT-ONCO-BIO-023), but its established multiple TKI generations and combination landscape indicate heavier current crowding (C1-EV_TRACTABILITY_0001, C1-CAT-ONCO-BIO-088). KRAS is also crowded: G12C inhibitors are clinically validated and the field is expanding rapidly (C2-EV_TRACTABILITY_0001, C2-CAT-ONCO-BIO-091b, C2-CAT-ONCO-BIO-088), so crowding raises biological confidence while reducing strategic value. Because neither dossier supplies a direct phase-by-phase competitor pipeline or patent landscape, the margin is narrow rather than clear.	A directly comparable competitor pipeline by phase in NSCLC for EGFR and KRAS. A target-specific patent and freedom-to-operate landscape, including composition-of-matter and mutation-specific claims. Direct evidence quantifying indication-expansion success beyond NSCLC for each target. Evidence comparing platform reuse and development timelines across additional KRAS alleles versus EGFR variants and modalities.	Bei welchen Krankheitsindikationen spielt KRAS eine spezifische Rolle? Wie ist der aktuelle Stand der Forschung zu KRAS? Ist ein mutationsspezifisches Targeting von KRAS realisierbar? Gibt es potenzielle alternative Zielstrukturen für KRAS? Bei welchen Krankheitsindikationen spielt EGFR eine spezifische Rolle? Wie ist der aktuelle Stand der Forschung zu EGFR? Multiple approved TKI generations Gibt es potenzielle alternative Zielstrukturen für EGFR? Clinically validated tractability Ist ein mutationsspezifisches Targeting von KRAS realisierbar? Wie ist der aktuelle Stand der Forschung zu EGFR?
ALK — EGFR	Safety and essentiality	A wins	gpt-5.6-luna	80%	FIRST (ALK) has the more favourable anticipated on-target safety profile. The ALK knockout mouse evidence reports viable and fertile homozygous animals with specific reproductive and neuroendocrine phenotypes, supporting limited essentiality in adult normal tissues, and the dossier also asserts narrow adult expression. In contrast, EGFR loss produces severe epithelial developmental defects involving lung, skin, and gastrointestinal tissues, while EGFR is broadly involved in epithelial homeostasis and regeneration; its on-target inhibition is associated with dermatologic and gastrointestinal toxicity. The ALK clinical toxicities are important but are primarily evidence about specific ALK inhibitors and the small-molecule modality rather than proof of intrinsic ALK target essentiality. The margin is narrow because direct human ALK LoF and quantitative tissue-breadth evidence are missing.	Direct human ALK loss-of-function phenotype data and quantitative normal-tissue expression breadth, especially in adult lung and mucus-producing glandular cells. Comparable direct human genetic and tissue-expression data for EGFR versus ALK in the specified cell context.	Wild-type ALK appears to have limited essentiality for survival of adult normal tissues, although loss of ALK produces specific reproductive and neuroendocrine phenotypes in mice. Favourable on-target safety Welcher Phänotyp tritt auf, wenn EGFR deletiert wird? Welche Gewebe oder Organsysteme sind bei der Maus nach dem Knockout des EGFR-Gens betroffen? Wie ist das Expressionsmuster von EGFR im Normalzustand im Vergleich zum Krankheitszustand? On-target dermatologic and GI toxicity ALK inhibition has a generally manageable clinical safety profile but carries clinically important risks, including hepatotoxicity, interstitial lung disease/pneumonitis, QT prolongation, bradycardia, severe visual loss, and embryo-fetal toxicity. Alectinib has clinically important hepatotoxicity and other organ toxicities that complicate the safety case for ALK inhibition. First-line lorlatinib produces a high burden of metabolic, neurologic and other adverse events, with more grade 3–4 toxicity than crizotinib. Welche Rolle spielt EGFR in gesunden Zellen/Geweben? Welche zellulären Prozesse werden durch EGFR in gesundem Gewebe im Vergleich zu erkranktem Gewebe reguliert?
ALK — EGFR	Novelty, crowding, and strategic optionality	A wins	gpt-5.6-luna	67%	ALK has the stronger direct evidence for strategic optionality: an established small-molecule and companion-diagnostic platform, demonstrated expansion into adjuvant resectable disease, and an explicitly documented next-generation/fourth-generation inhibitor pipeline addressing compound resistance mutations (C1-EV_TRACTABILITY_0005, C1-EV_TRACTABILITY_0006, C1-EV_COMPETITIVE_0005). However, ALK is also explicitly highly crowded, with multiple preferred first-line TKIs and limited differentiation among some agents; this reduces strategic value even while increasing biological and clinical confidence (C1-EV_COMPETITIVE_0001, C1-EV_COMPETITIVE_0006). EGFR has evidence of multiple drug modalities and relevance across several indications (C2-CAT-ONCO-BIO-046, C2-CAT-ONCO-BIO-091b), but the dossier lacks a comparable phased competitor pipeline, patent landscape, or indication-expansion program. Therefore FIRST is favored narrowly on documented optionality, while the conclusion is limited by incomplete and asymmetric evidence for EGFR crowding and intellectual property.	A directly comparable EGFR competitor pipeline by phase in NSCLC, including emerging modalities and differentiation versus current EGFR therapies. Patent-landscape evidence for both ALK and EGFR, including freedom-to-operate, composition-of-matter or use patents, and remaining exclusivity. Comparative indication-expansion evidence for EGFR showing actual clinical or development-stage expansion beyond NSCLC rather than general targetability across tumor types. A head-to-head assessment of strategic crowding for EGFR versus ALK in NSCLC.	ALK-positive NSCLC is a highly competitive targeted-therapy segment with three preferred first-line ALK TKIs—alectinib, brigatinib, and lorlatinib—and no direct randomized head-to-head trials establishing superiority among them. Competition is extending toward fourth-generation ALK inhibitors designed to address compound resistance mutations that can emerge after lorlatinib. ALK-directed oral therapy is tractable beyond metastatic disease, including adjuvant treatment after complete resection. ALK-targeted therapy has an established companion-diagnostic infrastructure, supporting practical biomarker selection and deployment of the modality. Bei welchen Krankheitsindikationen spielt EGFR eine spezifische Rolle? Ist ein mutationsspezifisches Targeting von EGFR realisierbar? ALK-positive NSCLC is a highly competitive targeted-therapy segment with three preferred first-line ALK TKIs—alectinib, brigatinib, and lorlatinib—and no direct randomized head-to-head trials establishing superiority among them. Ensartinib adds a newly approved first-line competitor with clinically meaningful PFS improvement over crizotinib, but its differentiation is not yet established against preferred next-generation ALK TKIs. Direct head-to-head evidence did not show brigatinib was superior to alectinib after crizotinib failure, indicating limited differentiation among ALK inhibitors.
EGFR — ALK	Clinical validation	B wins	gpt-5.6-luna	95%	ALK has substantially stronger indication-relevant clinical validation. Its dossier includes regulatory biomarker selection, multiple randomized phase 3 trials in ALK-positive NSCLC, chemotherapy-controlled evidence, superiority on progression-free survival and response endpoints, intracranial efficacy, long-term follow-up, and an adjuvant approval. The evidence also directly supports the small-molecule modality and clinical deployment through approved dosing and companion diagnostics. EGFR is supported by approved EGFR-directed drugs and broad claims of clinical validation in EGFR-mutated NSCLC, but the supplied dossier provides far less trial-level detail on dose, exposure, design, population, and endpoints. ALK's limitations—crossover-confounded overall survival in PROFILE 1014 and resistance or nonproductive-rearrangement issues—do not overturn the much stronger aggregate clinical validation, because they qualify durability or biomarker implementation rather than negate demonstrated target engagement and efficacy.	For EGFR, indication-matched randomized clinical-trial data with explicit molecule, dose, achieved exposure, comparator, biomarker-defined population, and endpoint results comparable in detail to the ALK dossier. For both candidates, direct clinical validation specifically in newly diagnosed NSCLC with the stated mucus-producing glandular-cell context and chemotherapy backbone.	ALK is clinically validated as a predictive therapeutic biomarker in advanced NSCLC by randomized phase 3 evidence showing superior efficacy of ALK inhibition over platinum-pemetrexed chemotherapy. Second-generation ALK inhibition provides superior systemic and intracranial disease control compared with first-generation therapy in untreated advanced ALK-positive NSCLC. Brigatinib demonstrated superior first-line efficacy, including intracranial activity, versus crizotinib in ALK-positive advanced NSCLC. Lorlatinib provides durable long-term clinical benefit in treatment-naive advanced ALK-positive NSCLC, with sustained systemic and intracranial disease control. Ensartinib provides regulatory-confirmed clinical validation of ALK as a treatment target in previously untreated locally advanced or metastatic NSCLC. ALK rearrangement is a validated predictive biomarker for ALK-targeted therapy in metastatic NSCLC. In untreated advanced ALK-positive NSCLC, biomarker-selected patients derived substantially greater benefit from ALK inhibition with crizotinib than from platinum-pemetrexed chemotherapy. ALK is clinically tractable with an established oral small-molecule kinase-inhibitor modality in metastatic NSCLC. ALK-directed oral therapy is tractable beyond metastatic disease, including adjuvant treatment after complete resection. Ist ein mutationsspezifisches Targeting von EGFR realisierbar? Wie ist der aktuelle Stand der Forschung zu EGFR? The pivotal PROFILE 1014 trial did not demonstrate a statistically significant overall-survival benefit for first-line crizotinib in the unadjusted analysis. ALK positivity does not ensure durable dependence on ALK signaling because resistance can arise through both on-target and off-target mechanisms. ALK FISH positivity can represent a nonproductive rearrangement rather than an expressed, targetable ALK fusion.
KRAS — ALK	Modality–direction–exposure fit	B wins	gpt-5.6-luna	82%	ALK has the stronger modality–exposure precedent: multiple oral small-molecule ALK inhibitors are clinically validated, with documented systemic and intracranial activity and benefit versus chemotherapy in previously untreated ALK-positive NSCLC. This directly supports achieving sustained inhibitory exposure with the proposed modality. KRAS also has strong small-molecule tractability, but the dossier provides substantially less direct PK/PD, delivery, or biodistribution evidence, particularly in the specified mucus-producing glandular cell context. The conclusion is narrow because neither dossier directly establishes exposure or duration in that exact cell type, and ALK dependence and biomarker productivity are heterogeneous across tumors.	For both candidates, direct PK/PD, biodistribution, and target-engagement measurements in mucus-producing glandular lung cells or corresponding NSCLC PDX tissue; target-turnover and duration-of-inhibition data under the proposed dosing regimen.	Several approved ALK TKIs ALK is clinically tractable with an established oral small-molecule kinase-inhibitor modality in metastatic NSCLC. First-line ALK inhibition produces strong systemic and intracranial clinical efficacy, supporting high tractability of ALK in NSCLC. Alectinib demonstrates that selective, CNS-penetrant ALK inhibition is an effective modality in treatment-naive advanced NSCLC. In untreated advanced ALK-positive NSCLC, biomarker-selected patients derived substantially greater benefit from ALK inhibition with crizotinib than from platinum-pemetrexed chemotherapy. ALK is clinically validated as a predictive therapeutic biomarker in advanced NSCLC by randomized phase 3 evidence showing superior efficacy of ALK inhibition over platinum-pemetrexed chemotherapy. Clinically validated tractability ALK rearrangement does not uniformly establish ALK pathway dependence across NSCLC models. ALK fusion variants produce materially different pathway dependency and inhibitor sensitivity. ALK rearrangement is frequently subclonal or unevenly distributed across NSCLC tumor cells rather than present uniformly throughout the tumor. ALK FISH positivity can represent a nonproductive rearrangement rather than an expressed, targetable ALK fusion.
EGFR — MET	Human natural experiments	B wins	gpt-5.6-luna	88%	MET is better supported because human pharmacological evidence in the biomarker-defined MET exon 14–skipping NSCLC subgroup shows substantial responses in treatment-naive and previously treated patients, with durable activity and established regulatory use for selective MET inhibition (C2-EV_SAFETY_0002, C2-EV_SAFETY_0005, C2-EV_CLINICAL_0001, C2-EV_CLINICAL_0002, C2-EV_CLINICAL_0003). The genetic direction is concordant: MET exon 14 skipping removes negative regulation, activates MET, and supports inhibition as the therapeutic direction (C2-EV_GENETICS_0002, C2-EV_MECHANISM_0002). Tolerability is not risk-free, with edema, interstitial lung disease, hepatotoxicity, and other toxicities reported (C2-EV_SAFETY_0004, C2-EV_SAFETY_0006, C2-EV_SAFETY_0007), but these are characterized as monitorable rather than eliminating the human efficacy/tolerability signal. EGFR has strong somatic gain-of-function and pharmacologic rationale, but the dossier does not provide comparably direct human efficacy-and-tolerability natural-experiment evidence for EGFR inhibition; its germline loss-of-function evidence also does not support inhibition as a therapeutic direction, and on-target toxicity is documented (C1-EV_SAFETY_0001).	For EGFR, a human pharmacological natural-experiment or long-term exposure cohort directly demonstrating efficacy and tolerability of EGFR inhibition in NSCLC would most change the comparison. For MET, a non-trial long-term exposure cohort would better establish tolerability as a natural experiment.	MET exon 14–altered NSCLC shows clinically meaningful dependence on MET signaling, supporting MET as an essential therapeutic driver in this molecular subset. A second selective MET inhibitor confirms both target dependence and a clinically relevant toxicity burden in MET exon 14–skipping NSCLC. MET exon 14 skipping is clinically validated as a predictive biomarker in metastatic NSCLC through durable responses to selective MET inhibitors. Tepotinib has traditional FDA approval for metastatic NSCLC harboring MET exon 14 skipping alterations, with efficacy confirmed in a 313-patient dataset. Capmatinib is FDA-indicated for metastatic NSCLC with a mutation leading to MET exon 14 skipping, selected using an FDA-approved test. Clinical targeting of MET has substantial but monitorable toxicity, including edema, interstitial lung disease, hepatotoxicity, pancreatic toxicity, and embryo-fetal toxicity. Tepotinib has clinically important, potentially fatal pulmonary toxicity in MET-altered NSCLC. Tepotinib safety includes hepatotoxicity, pancreatic enzyme elevations and embryo-fetal toxicity requiring monitoring or treatment modification. MET immunohistochemical positivity did not identify a clinically responsive NSCLC population in the phase III METLung trial. Adding the MET inhibitor tivantinib to erlotinib failed to improve overall survival in the phase III ATTENTION trial. On-target dermatologic and GI toxicity
KRAS — MET	Integrated therapeutic hypothesis	Abstained	gpt-5.6-luna	99%	The dossier contains substantial comparative evidence, but the stated guardrail explicitly requires Q20 to be run only after Q1–Q19 have been scored and compared with the Q20 posterior. Those prerequisite scores and composite are absent, so a compliant integrated-hypothesis verdict cannot be issued.	Completed Q1–Q19 scores for both candidates and the resulting criterion-weighted composite, enabling the required Q20 coherence review.	–
EGFR — ALK	Druggability and tractability	B wins	gpt-5.6-luna	77%	Both targets have strong small-molecule precedent. EGFR has multiple approved TKIs, available tool compounds, mutation-informed binding-site tractability, and extensive lung-model precedent (C1-EV_TRACTABILITY_0001, C1-CAT-ONCO-BIO-115, C1-CAT-ONCO-BIO-010, C1-CAT-ONCO-BIO-032b). ALK has equally strong but more directly documented modality and deployment evidence: several approved oral TKIs, regulatory confirmation, companion-diagnostic infrastructure, and systemic plus intracranial efficacy in untreated NSCLC (C2-EV_TRACTABILITY_0001 through C2-EV_TRACTABILITY_0006). ALK therefore has a narrow advantage for tractability in the specified lung/small-molecule setting because the dossier provides clearer evidence of clinically deployable selectivity, oral delivery, CNS-accessible exposure, and biomarker-linked use. This is not a clear margin because direct pocket-quality metrics, experimental structural comparisons, and delivery data in the specified mucus-producing glandular cells are absent for both candidates.	Direct head-to-head experimental structures, pocket-quality metrics, binding kinetics, and selectivity profiles for EGFR versus ALK in the specified mucus-producing glandular lung-cell context. Direct delivery, target-engagement, and pharmacodynamic data in mucus-producing glandular cells and in the specified lung PDX model for both targets. Comparative protein-turnover or degradation data under small-molecule inhibition in the specified tissue context.	Several approved ALK TKIs ALK is clinically tractable with an established oral small-molecule kinase-inhibitor modality in metastatic NSCLC. First-line ALK inhibition produces strong systemic and intracranial clinical efficacy, supporting high tractability of ALK in NSCLC. Alectinib demonstrates that selective, CNS-penetrant ALK inhibition is an effective modality in treatment-naive advanced NSCLC. ALK-targeted therapy has an established companion-diagnostic infrastructure, supporting practical biomarker selection and deployment of the modality. Multiple approved TKI generations Welche Toolverbindungen für EGFR sind verfügbar? Gibt es veröffentlichte Studien, in denen die verfügbaren Tool-Substanzen zur Validierung von EGFR in präklinischen Modellen eingesetzt wurden? Verändern Mutationen in EGFR bestehende medikamentös adressierbare Stellen? On-target dermatologic and GI toxicity The ALK small-molecule modality is vulnerable to acquired on-target resistance, particularly after sequential inhibitor treatment. ALK inhibition has a generally manageable clinical safety profile but carries clinically important risks, including hepatotoxicity, interstitial lung disease/pneumonitis, QT prolongation, bradycardia, severe visual loss, and embryo-fetal toxicity. Alectinib has clinically important hepatotoxicity and other organ toxicities that complicate the safety case for ALK inhibition. First-line lorlatinib produces a high burden of metabolic, neurologic and other adverse events, with more grade 3–4 toxicity than crizotinib.
EGFR — KRAS	Time to decisive experiment	Abstained	gpt-5.6-luna	96%	Both dossiers provide evidence that tool compounds and published preclinical, including PDX-related, studies exist for the targets (C1-CAT-ONCO-BIO-010; C1-CAT-ONCO-BIO-115; C2-CAT-ONCO-BIO-010; C2-CAT-ONCO-BIO-115). However, the criterion asks which organisation can reach a high-information in vivo decision faster and at lower cost. Neither dossier supplies organisation-specific capacity, historical cycle times, exact model readiness, procurement lead times, or study costs. The available evidence therefore cannot support a directional comparison; this is not a positive tie claim.	Organisation-specific internal capability and capacity for the stated lung NSCLC PDX in vivo proof-of-concept study. Historical cycle times from target selection through decisive in vivo readout for each target. Direct cost, procurement lead time, and validated availability of the exact patient-derived xenograft, mucus-producing glandular-cell model, genomic-biomarker assays, and dosing reagents. A head-to-head operational plan showing which target would produce a decisive go/no-go result sooner.	Gibt es veröffentlichte Studien, in denen die verfügbaren Tool-Substanzen zur Validierung von EGFR in präklinischen Modellen eingesetzt wurden? Welche Toolverbindungen für EGFR sind verfügbar? Gibt es veröffentlichte Studien, in denen die verfügbaren Tool-Substanzen zur Validierung von KRAS in präklinischen Modellen eingesetzt wurden? Welche Toolverbindungen für KRAS sind verfügbar?

PreviousPage 5 of 5